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Aims We identified 10 patients with disseminated Mycobacterium chimaera infections subsequent to open-heart surgery
at three European Hospitals. Infections originated from the heater–cooler unit of the heart– lung machine. Here we
describe clinical aspects and treatment course of this novel clinical entity.
Methods
and results
Interdisciplinary care and follow-up of all patients was documented by the study team. Patients’ characteristics, clinical
manifestations, microbiological findings, and therapeutic measures including surgical reinterventions were reviewed and
treatment outcomes are described. The 10 patients comprise a 1-year-old child and nine adults with a median age of 61
years (range 36–76 years). The median duration from cardiac surgery to diagnosis was 21 (range 5–40) months. All
patients had prosthetic material-associated infections with either prosthetic valve endocarditis, aortic graft infection,
myocarditis, or infection of the prosthetic material following banding of the pulmonary artery. Extracardiac manifesta-
tions preceded cardiovascular disease in some cases. Despite targeted antimicrobial therapy,M. chimaera infection re-
quired cardiosurgical reinterventions in eight patients. Six out of 10 patients experienced breakthrough infections, of
which four were fatal. Three patients are in a post-treatment monitoring period.
Conclusion Healthcare-associated infections due toM. chimaera occurred in patients subsequent to cardiac surgery with extracor-
poreal circulation and implantation of prosthetic material. Infections became clinically apparent after a time lag of
months to years. Mycobacterium chimaera infections are easily missed by routine bacterial diagnostics and outcome is
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poor despite long-term antimycobacterial therapy, probably because biofilm formation hinders eradication of
pathogens.
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Introduction
Non-tuberculous mycobacteria (NTM) can cause pulmonary dis-
ease, particularly in patients with pre-disposing structural lung dis-
ease, skin, soft tissue and bone infections, endocarditis, and
disseminated infections in immunocompromised hosts. Signs and
symptoms are variable and often non-specific. Also, a growing num-
ber of case reports of cardiosurgical site infections due toNTM have
been reported in recent years.1–5 Thus far, only rapid-growing NTM
have been found to be associated with prosthetic valve endocarditis
(PVE).1– 4,6 Recently, we published two cases of PVE and blood-
stream infection due to Mycobacterium chimaera,7 a slow-growing
NTM and member of the M. avium complex (MAC)8 that has previ-
ously been cultured from tapwater in patients’ households.9
Cardiosurgical outbreaks of NTM infections have been associated
with contaminated water used for the cardioplegia solution,2 con-
tamination during the manufacturing process4 or use of a contami-
nated patch for septum defect repair,3 but source identification
often failed.7,10 In the course of an outbreak at the Zurich Heart
Center,M. chimaerawas cultured from air sampling in the operating
theatre and from water tanks of from heater–cooler units (HCUs)
serving the heart– lung machine. Identical randomly amplified poly-
morphic DNA–polymerase chain reaction (RAPD-PCR) results in-
dicated that patients were infected by intraoperative contamination
of the surgical site due to airborne transmission of microorganisms
sprayed from the ventilation outlet of HCUs into the operating the-
atre.11,12 As of February 2015 a total of six cases were identified in
Zurich (Switzerland). Another four patients were detected in paral-
lel in Freiburg, Zwolle and Rotterdam, where the notification of na-
tional public health authorities led to thorough investigation of the
respective HCUs pointing to a similar transmission route. On 30
April 2015, an alert was published by the European Centre for Dis-
ease Prevention and Control, warning healthcare providers in care
of patients who have undergone open-heart surgery to be vigilant
for cases of endocarditis or other cardiovascular infections of un-
known origin and consider testing mycobacteria.13,14 Here we aim
to give a comprehensive description of the clinical manifestations
and outcome of this novel disease entity. In addition, we provide ex-
posure criteria and a case definition to facilitate the detection of po-
tential cases on a global level.
Methods
Exposure criteria
A former open-heart surgery and implantation of a cardiovascular
implant were our exposure criteria.
Case definition
Our clinical criteria were: PVE, prosthetic vascular graft infection
(PVGI), or disseminated infection including embolic and immunologic
manifestations.
Confirmed cases
Confirmed cases were defined as cases meeting the clinical and expos-
ure criteria and M. chimaera proven by culture or polymerase chain re-
action (PCR) identification from an invasive sample from the cardiac
surgery site.
Probable cases
Probable cases were defined as cases meeting the clinical and exposure
criteria and detection of M. chimaera or M. avium complex in blood
and/or extracardiac tissue cultures.
Case finding
Mycobacterial cultures are not part of the routine microbiological
workup in the case of cardiovascular infections. The first patient was de-
tected by a thorough histopathological analysis of cardiac tissue, which
triggered a PCR for non-tuberculous mycobacteria yielding the diagno-
sis.7 The remaining patients were detected based on direct 16S rRNA
gene-sequencing results of cardiac tissue or bone or on positive myco-
bacterial blood cultures.
Microbiology of Mycobacterium chimaera
Standard methods were used to culture mycobacteria, using the MGIT
960 system (Becton DickinsonMicrobiology Systems, Sparks, MD, USA)
andMiddlebrook 7H11 agar plates incubated at 378C for 7 weeks or un-
til positive. In Zurich, 16S rRNA gene sequencing was performed as de-
scribed before.15 Antimicrobial susceptibility testing was performed in
the MGIT 960 system equipped with the TB Exist module for rifampin,
rifabutin, amikacin, ofloxacin, moxifloxacin, clarithromycin, and etham-
butol.16 The German strain was identified by sequencing of the 16S
rRNA gene and the 16S-26S rRNA Gene Internal Transcribed Spacer,
the Dutch strains were identified by the Inno-LiPA Mycobacteria v2
line probe assay, which features a specific probe for M. chimaera. The
MICs of the German and Dutch strains were determined by broth mi-
crodilution in cation-adjusted Mueller Hinton Broth, as recommended
by CLSI (document M24-A2, 2011).17
Clinical investigations
We obtained patient informed consent to publish their clinical data. Co-
morbidities were quantified using the Charlson comorbidity index.18
The information on index surgery included American Society of Anaes-
thesiologists (ASA) score,19 type of operation, timing of operation, and
the extracorporeal circulation time. All patients were assessed accord-
ing to the modified Duke criteria.20We collected treatment information
and, if available, results of therapeutic drug monitoring. In all patients,
transthoracic (TTE) and transoesophageal echocardiography (TEE)
was performed. Histopathological features of infected tissue before or
P. Kohler et al.2746
after initiation of antimicrobial treatment were collected. In Zurich, pa-
tients were screened for ophthalmologic manifestations of the disease,
including fundoscopy and multimodal imaging.
We assumed treatment failure if the patient died due to uncontrolled
infection or if a patient showed a positive culture forM. chimaera despite
antimicrobial therapy for at least 3 months.
Results
Population at risk and prevalence
In Zurich, Switzerland, cases were associated with procedures be-
tween 13 August 2008 and 30 May 2012. During this period a total
of 3706 cardiosurgical procedures with extracorporeal circulation
were conducted. We identified six disseminated M. chimaera cases,
corresponding to a cross-sectional prevalence of 0.16%. Other pa-
tients with M. chimaera cardiac infection were not detected despite
extensive case finding strategies.11
After the detection of the first case at the Freiburg University
Hospital, Germany, a national alert was issued. In the Netherlands,
the second case was identified after publication of the first case in a
national newsletter. Review of charts of patients with positive
M. chimaera cultures yielded one paediatric case in Rotterdam.
A case finding protocol has now been implemented in Germany
and the Netherlands nationwide.
Patient characteristics
Overall, nine confirmed cases including eight adults and one
child, and one probable case are described. For the adult patients
the median age and median BMI were 61 years (range, 36–76)
and 24.9 kg/m2 (23.4–35.7), respectively. Details on the index car-
diac surgery are shown in Table 1. The median extracorporeal circu-
lation time was 191 min (range, 123–294). Two patients had
diabetes mellitus, one patient received azathioprine and salazopyr-
ine for Crohn’s disease, and one patient had lymphocytopenia of
unknown origin. After the index surgery, two patients received
corticosteroid treatment for presumptive sarcoidosis and one pa-
tient received repetitive intra-articular methotrexate for suspected
rheumatologic disease. All patients were HIV negative.
The child with a congenital cardiac anomaly was in neonatal age
when he received a correction of the aortic anomalies and banding
of the pulmonary artery.
Manifestations of disease
The most common initial complaints in adults were fever, shortness
of breath, fatigue, and weight loss. Physical findings were non-
specific with the exception of splenomegaly. All patients had an-
aemia, pronounced lymphocytopenia, and thrombocytopenia.
C-reactive protein, lactate dehydrogenase, transaminases, and cre-
atinine levels were elevated in all subjects. In the infant, clinical sus-
picion arose due to fever episodes and failure to thrive. A summary
of the presenting clinical signs and laboratory analyses are shown in
Supplementary material online, Table S1, which occurred after a me-
dian incubation time of 18 (range, 11–40) months. Details on the
microbiological and histopathological findings are summarized in
Supplementary material online, Table S2.
Confirmed cases
Cardiac manifestations
Five of the nine patients with confirmed diagnosis presented with
PVE, two with PVGI and one with myocarditis. The child presented
with infection of the prosthetic band and a mycotic aneurysm of the
pulmonary artery. All diagnoses were made upon cardiosurgical re-
intervention with cultures or PCR from cardiac tissue being positive
for M. chimaera. No other microorganisms were detected in the
blood, and there was no serological evidence of a culture-negative
endocarditis of other cause (i.e. Bartonella spp., Brucella spp., Coxiella
burnettii, Tropheryma whipplei). Diagnosis was delayed with a median
duration between index surgery and culture confirmed diagnosis of
almost 2 years (21 months; range, 5–40). Affected patients pre-
sented with prevailing cardiac complications like severe valve insuf-
ficiency and subsequent reduction in ejection fraction, paravalvular
abscess, or pseudoaneurysm formation (Figure 1). The TEE showed
paravalvular regurgitation or leakage, anteroseptal pseudoaneurysm
as well as a paravalvular abscess with extension into the interatrial
septum (Figure 1A). Additionally, vegetations or multiple short,
thin and sparse filaments on the ventricular side were detected
(Figure 1B).
Extracardiac manifestations
In six of nine patients with confirmed diagnosis extracardiac manifes-
tations preceded cardiac disease. Among the first disease manifesta-
tions were bone infections (osteoarthritis, spondylodiscitis, or sternal
wound infection together with a large retrosternal abscess forma-
tion), cholestatic hepatitis, nephritis, or blood stream infection. Myco-
bacterial blood cultures were positive a priori in four patients. At the
time of diagnosis, most patients had splenomegaly. In the course of
the disease, patients developed bi- or even pancytopenia, panuveitis,
or multifocal chorioretinitis (Figure 1H), pneumonitis (Figure 1E) or
cerebral vasculitis. One patient developed a surgical site infection
with M. chimaera at the removal site of the saphenal vein.
Probable case
The probable case (Table 1, Patient 9) presented with fever of un-
known origin subsequent to open heart surgery. He had been treated
for presumptive sarcoidosis due to granulomatous hepatitis, but per-
sistent fever prompted new diagnostic procedures including a PET/
CT scan. Diagnosis of M. chimaera infection was ascertained after bi-
opsy of the right sternoclavicular joint, bone marrow, liver, and blood
cultures. However, TEE did not reveal any signs of endocarditis.
Antimicrobial therapy
The detailed time course of events and treatment information is de-
picted in Figure 2. Targeted antimicrobial therapy consisted of cla-
rithromycin or azithromycin, rifabutin or rifampicin, ethambutol,
plus/minus amikacin, or moxifloxacin. The number of available ana-
lyses, mean drug doses, serum maximum observed concentration
levels, and the percentage of analyses revealing subtherapeutic
drug concentrations are recorded in Supplementary material online,
Table S3. In more than half of the cases the recommendedmacrolide
drug levels were not reached. The same holds true for rifabutin, eth-
ambutol, moxifloxacin, and amikacin. Antimicrobial drugs, tested
drug concentrations, and phenotypic drug susceptibilities of patient
Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections 2747
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of patients with invasive infection due to M. chimaera at time of the index cardiac surgery
Patient no.
1a 2a 3 4 5 6 7 8 9 10
Characteristics
Sex Male Male Male Male Male Male Male Female Male Male
Age, years 58 51 64 49 61 63 76 36 74 1
BMI, kg/m2 30.1 24.2 23.4 29.4 30.6 24.9 24.4 35.7 24.3 na
Active or former
smoker
Yes Yes No Yes No Yes No No No No
Alcohol useb No Yes No Yes No No No No No No
Comorbidities COPD
Diabetes mellitus
Sarcoidosisc
Herpes zoster Mild renal insufficiency,
Rheumatoid arthritisc
Crohn’s disease
COPD
None Severe renal
insufficiency
Hypertension
CHD
Cardiomyopathy Diabetes mellitus
CHD
Hypertension
Hyperlipidemia
Mild renal insufficiency
None
Charlson Comorbidity
Index
5 1 2 2 1 1 1 1 6 0
Immune status
HIV serologyd Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
IFNg autoantibodiesd nd nd Negative Negative nd Negative nd nd nd nd
Lymphocytes, G/L 2.09 1.44 1.61 1.66 0.35 1.37 0.75 1.0 0.46 0.66
Immunosuppression Steroidsc None Methotrexatec Azathioprine
Sulfasalazine
None None None None Steroids None
Cardiac surgerye
Reason for surgery Mitral insufficiency
CHD
Aortic dissection Mitral insufficiency Aortic valve
stenosis
Aneurysma spurium
of descending
aortaf
Aortic valve
dissection
Aortic valve
stenosis CHD
Mitral valve insufficiency
Dilated
cardiomyopathy
Aortic valve stenosis
CHD
Congential cardiac
anomaly
Type of surgery Mitral valve
reconstruction
Composite graft
replacement
Mitral valve
reconstruction
Aortic valve
replacement
Aortic root and arch
replacement
Aortic root and
arch
replacement
Aortic valve
replacement
Mitral valve
robofaciltated
reconstruction
Aortic valve replacement
combined with
CABG
Aortic arch
reconstruction
Coarctectomie
Ductal closure Allograft
patch enlargement
of the arch Banding
of the pulmonary
artery
Date of index cardiac
surgery
13.08.2008 29.01.2010 12.06.2009 31.10.2009 30.05.2012 26.03.2012 22.08.2011 23.04.2013 16.01.2013 07.04.2011
ASA score 3 5 3 3 4 5 3 4 4 na
Emergency No No No Yes Yes Yes No No No No
ECC time 191 150 210 166 235 272 123 294 158 na
CHD, coronary heart disease; CABP, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; BMI, body mass index; HIV, human immunodeficiency virus; IFNg, interferon gamma; ASA, American Society of Anesthesiology;
ECC, extracorporeal circulation time; na, not available
aPatients 1–6.7,11
bAlcohol use: severe (female subjects, 140 g/day; male subjects, 160 g/day) or moderate (female subjects, 20–40 g/day; male subjects, 40–60 g/day).
cDiagnosis or treatment initiation after index surgery.
dInvestigation done after manifestation of the disease.
eImplants differed in types of material and manufacturers.
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isolates are provided in Table 2. Drug susceptibility testing of break-
through isolates was unchanged.
Outcome
At least eight patients experienced therapy failure according to our
definition. Five patients died, four of them due to uncontrolled
M. chimaera infection despite being under targeted combination
therapy for 15, 31, 270, and 375 days, respectively. Tissue cultures
from Patient 3 (bone and annuloplasty ring (Figure 1G)), Patient 4
(sternoclavicular mass, epicardial pacemaker wire), Patient 8 (annu-
loplasty ring) and blood cultures from Patients 6 and 9 became posi-
tive for M. chimaera despite prolonged antimicrobial therapy
Figure 1 Clue echocardiographic findings of patient four and five with M. chimaera prosthethic valve endocarditis after open-heart surgery
(A–D). Histopathological findings of pulmonary (E) and cardiac tissue (F) of Patient 2. Biofilm formation on mitral ring of Patient 3 after 12 months
of antimycobacterial therapy (G), and fundoscopy of Patient 5 while being on treatment for almost 6 months (H ). (A) Patient 4 at presentation.
Mid-oesophageal biplane view of the aortic mechanical prosthesis (ATS 24 mm) with a paravalvular abscess as well as an anteroseptal pseudoa-
neurysm. (B) Patient 5 at presentation. Midesophageal long-axis view showing an echo-dense structure around the aortic valve prosthesis suggest-
ing a local inflammation as well as multiple sparse and thin filaments with a maximal length of 10 mm. (C) Patient 4 after replacement of the
mechanical prosthesis with a Freestyle bioprosthesis 25 mm in 2013 and after more than 6-month of antibiotic therapy. Amid-oesophageal biplane
view focusing on aortic root and interatrial septum is shown. A moderately echodense and slightly inhomogenous mass surrounds the aortic valve,
extends into the interatrial septum, and protrudes into the right atrium consistent with a persistent infection. (D) Patient 5- after 6-month of ther-
apy. Mid-oesophageal view showing multiple, persistent, sparse, and thin filaments correlating with therapy-recalcitrant endocarditis.
Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections 2749
(median 8 months, range 0.5–12). Persistent signs of infection
(Patients 4 and 5, Figure 1C and D) and progressive chorioretinal le-
sions (Patient 5, Figure 1H) represented an indication for immediate
cardiosurgical reintervention. Of note, all these patients were pre-
viously considered inoperable due to presumptively high periopera-
tive mortality, but the risk to benefit assessment changed in the light
of uncontrolled M. chimaera infection. Currently, three patients are
in a post-treatment monitoring period.
Discussion
As of February 2015, 10 heart surgery patients from four hospitals in
three different European countries have been diagnosed with disse-
minatedM. chimaera infection. Airborne contamination of the oper-
ation region and/or prosthetic material with M. chimaera during
cardiac surgery is the most likely source of infection.11 This new clin-
ical entity may manifest itself after an incubation time of several
months or even years after surgery. The patients present with non-
specific clinical signs and symptoms and a variety of local or dissemi-
nated infection sites, which may hamper the diagnosis. Furthermore,
diagnosis of mycobacterial infection is delayed as culture for myco-
bacteria is not part of the routine diagnostic work-up. Despite
surgical reintervention and long-term antimicrobial therapy, the
outcome is mostly poor.
Based on the disease prevalence in the four affected centres, we
estimate a minimum of one to two M. chimaera infections per 1000
patients undergoing open-heart surgery. In total, 8 out of 16 tested
Swiss hospitals, one out of one tested German hospital, eight out of
eight tested Dutch hospitals performing cardio-surgical procedures
have detectedM. chimaera in the water system of their HCUs, and in
some hospitals also in air cultures of the operating theatre, suggest-
ing a high significance of our findings. In addition, a recent investiga-
tion from England reported thatM. chimaerawas found in the water
within HCUs (air investigation ongoing).21 Of note, until now cases
were only detected in hospitals where the HCUs are placed inside
the operating theatre, hence some public health authorities now
recommend to put HCUs outside the operating theatre.22,23 How-
ever, these epidemiological findings need to be extended. Ongoing
whole-genome sequencing efforts indicate a match between patient
isolates and air samples from the proximity of the heat cooler units.
In our patients, mycobacterial infection occurred in the absence
of severe immunodeficiency. Apart from infection of the cardiac
prosthetic material, disease manifestations were similar to what
has been described for other disseminated NTM disease. This in-
volves constitutional symptoms such as fever, night sweats and
Figure 2 Treatment and clinical course of M. chimaera cardiovascular infections. Note: Start of antimycobacterial therapy represents day 1.
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weight loss as well as non-specific laboratory findings such as an-
aemia and high lactate dehydrogenase serum levels. In most patients,
manifestation of bacteriemic embolization preceded symptoms of
cardiac infection. We therefore recommend a high clinical suspicion
for NTM infection in patients with cardiac prosthetic material and a
history of cardiac surgery presenting with signs of disseminated dis-
ease, e.g. osteomyelitis or other bone lesions, cholestatic hepatitis,
or granulomatous nephritis without identification of a causative
pathogen. The same accounts for patients with multifocal choriore-
tinitis or vasculitis of unknown origin. As routine blood cultures
have a low sensitivity for mycobacterial growth, suggested methods
for mycobacterial blood cultures include the BacTec myco Lytic/F
bottles (BD Bioscience) and the use of Isolator tubes (Isolator 10,
Oxoid; Isostatw System, WampoleTM). These cultures should be
performed multiple times on separate days to maximize their sensi-
tivity. In addition, maximum effort should be taken to obtain biopsy
or other samples of affected organs and tissues (e.g. bone, liver, and
bone marrow), specifically including cardiac valve samples for cul-
ture in specific mycobacteria media together with molecular diag-
nostics such as mycobacterial genus PCR.15
As in all foreign body infections, a removal of the prosthetic ma-
terial and a surgical debridement have to be thoroughly discussed
with the cardiovascular surgeon in the case of invasive infection
withM. chimaera.24 Excisional surgery without antimicrobial therapy
is not advisable, but the most appropriate timing of surgery is un-
known. If the diagnosis is made prior to surgical intervention, it is
prudent to wait for antimicrobial therapy in an attempt to steril-
ize/decrease the bacterial load at the site where prosthetic valves
have to be reinserted.
Mycobacterium chimaera strains were uniformly susceptible to cla-
rithromycin (MIC ,8 mg/L).25 We used the combination of cla-
rithromycin, rifabutin, and ethambutol as the basis of treatment
regimens.17 As for severe pulmonaryM. chimaera disease, it appears
prudent to add amikacin during the first 3 months of treatment,17
akin to staphylococcal and streptococcal endocarditis.26 No state-
ment can be made regarding the duration of treatment since there
are no data regarding cardiac implants infected with NTM. Accord-
ing to ATS/IDSA guidelines, a minimum of 12 months of therapy
after immune restoration is indicated for non-HIV patients with dis-
seminated MAC disease.17 Despite our attempts to optimize ther-
apy with therapeutic drug monitoring, breakthrough infection
occurred in most of patients. Low drug concentrations of macro-
lides, rifabutin, and moxifloxacin due to drug–drug interactions27
were recorded. The relevance of these findings remains unknown.
Macrolides have a strong tissue penetration and hence, serum con-
centration is much lower than the concentration at the surgical site.
A beneficial role of therapeutic drug monitoring has not yet been
proved in NTM diseases.27,28 Most anti-mycobacterial agents are as-
sociated with a high rate of side effects and increased macrolide or
rifabutin doses were not tolerated due to QT-interval prolongation
and liver or bone marrow toxicity. The in vitro activity against an or-
ganism may not necessarily translate to the in vivo situation, especial-
ly in the context of potential biofilm formation, where the
interpretation of traditional in vitro susceptibility testing is
problematic.29
Our findings have important implications. First, infections with
M. chimaera and other NTM have to be considered in the differential
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diagnosis of patients with previous cardiac surgery and extra-
corporeal circulation, even in the absence of severe immuno-
suppression. A few more case patients are already identified in
Europe21,30 and more cases are likely to be found in the future
when clinicians are alerted and, as a consequence of active case find-
ing (recommendation for case detection, Table 3). Second, HCUs as
potential source of M. chimaera and other waterborne microorgan-
isms in the operating theatre have to be identified and avoided by
either placing HCUs outside of the operating theatre with inde-
pendent air flow control, by making the water reservoir and piping
air-tight or by reliable disinfection of the water circuits and reser-
voirs. Recommendations for the prevention of these waterborne,
aerogenic infections in cardiac surgery are strongly warranted.
Third, these infections are recalcitrant to classic antimycobacterial
therapy, because of intrinsic antibiotic resilience, notoriously chal-
lenging infection sites such as bone tissue, and biofilm formation
on the cardiovascular implant. More studies are needed with regard
to the clinical phenotype of disseminated M. chimaera infection, its
epidemiology, virulence mechanisms, and susceptibility to
antibiotics.
Supplementary material
Supplementary Material is available at European Heart Journal online.
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